Brief: Madrigal Pharmaceuticals Q2 EPS USD -7.1
07/08/2024 12:00
Aug 07 (Reuters) - Madrigal Pharmaceuticals Q2 operating expenses USD 177.175 million. * Q2 operating income USD -162.537 million * Q2 net income USD -151.971 million
Recent news on Madrigal Pharmaceuticals
See all newsBrief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule
Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Madrigal Pharmaceuticals Q2 revenue rises 71% on Rezdiffra demand
U.S. RESEARCH ROUNDUP-Boeing, Coca-Cola, PayPal
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)